Drug Profile

ABI 1179

Alternative Names: ABI-1179

Latest Information Update: 05 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gilead Sciences
Developer Assembly Biosciences
Class Antivirals; Small molecules
Mechanism of Action DNA helicase-primase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Herpes simplex virus infections

Most Recent Events

20 Feb 2025 Safety and pharmacokinetics data from a phase Ia/Ib trial in Herpes simplex virus infections released by Assembly Biosciences
19 Dec 2024 Phase-I clinical trials in Herpes simplex virus infections in New Zealand (PO) prior to December 2024 (NCT06698575)
11 Nov 2024 Assembly Biosciences plans a phase I trial for Herpes simplex virus infection in New Zealand (PO) (NCT06698575)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com